streptokinase 中文意思是什麼

streptokinase 解釋
n. 名詞 【生物化學】鏈激酶。

  1. All the currently used thrombolytic agents are plasminogen activators, which are very efficient in restoring the blood flow. they can convert plasminogen into plasmin and thus degrade fibrin. despite the widespread use of established thrombolytic agents such as streptokinase, t - pa and u - pa, all these agents suffer from a number of inadequacies including resistance to reperfusion, occurrence of coronary reocclusion and bleeding complications

    介紹了國內外溶栓劑蛋白質工程方面的新進展，主要涉及了組織型纖溶酶原激活劑t - pa尿激酶型纖溶酶原激活劑u - pa鏈激酶sk葡萄球菌激酶sak dspa及tsv - pa的研究進展。
  2. They can convert plasminogen into plasmin and thus degrade fibrin. despite the widespread use of established thrombolytic agents such as streptokinase, t - pa and u - pa, all these agents suffer from a number of inadequacies including resistance to reperfusion, occurrence of coronary reocclusion and bleeding complications

    一些pa突變體及新型溶栓劑，如k2p tnk - pa和star等的臨床實驗結果表明它們在延長體內半壽期增強對血纖維蛋白選擇性和溶栓效率等方面有較大的改進。
  3. The comparison of the repass rate between homemade recombined streptokinase and urokinase in thrombolytic therapy of acute myocardial infarction

    國產重組鏈激酶與尿激酶在急性心肌梗死溶栓中的血管再通率的比較
  4. Comparison the effects of recombinant streptokinase and urokinase in acute myocardial infarction

    尿激酶對急性心肌梗死溶栓的療效分析
  5. Comparison of therapy with recombinant streptokinase and urokinase for acute myocardial infarction

    尿激酶溶栓治療急性心肌梗死的對比研究
  6. We conducted a trial to clarify the therapeutic role of intrapleural streptokinase

    我們進行了一項試驗，以闡明胸膜腔內應用鏈激酶的治療作用。
  7. Therapeutic efficacy of recombinant streptokinase and urokinase in the treatment of acute myocardial infarction

    重組鏈激酶與尿激酶治療急性心肌梗死的療效
  8. Intrapleural streptokinase for pleural infection a step forward in managing pleural effusions

    胸膜腔內滴注鏈激酶治療胸膜腔感染這是胸膜腔積液治療的進步嗎
  9. Conclusions the intrapleural administration of streptokinase does not improve mortality, the rate of surgery, or the length of the hospital stay among patients with pleural infection

    結論在胸膜感染的病人中，鏈激酶胸膜腔內給藥不能改善死亡率、手術率或住院時間的長短。
  10. The systemic administration of heparin, warfarin or streptokinase is determined to have a thrombolytic effect but risk systemic or ocular bleeding and appeare to be unhelpul for improving visual acuity

    全身應用肝素、華法令或鏈激酶溶栓藥物已被證實對提高視力沒有明確幫助，並且存在全身或局部出血的風險。
  11. The quest continues for plasminogen activators with higher potency, specific thrombolytic activity, fibrin selectivity and longer half - life time. the recent progress in the protein engineering of plasminogen activators, including t - pa, u - pa, streptokinase, staphylokinase and other novel plasminogen activators, was presented in this article

    一些pa突變體及新型溶栓劑，如k2p tnk - pa和star等的臨床實驗結果表明它們在延長體內半壽期增強對血纖維蛋白選擇性和溶栓效率等方面有較大的改進。
分享友人
分享到 Line

分享到臉書